Nerve-sparing total prostatectomy with or without adjuvant chemotherapy is associated with a low rate of surgical complications, long-term continence and improved survival in 22 dogs with T1 to T3 prostatic tumours.

Nerve-sparing prostatectomy provides good continence outcomes and survival for early-stage canine prostatic tumours.

This retrospective study evaluates nerve-sparing total prostatectomy outcomes in 22 dogs with early-stage prostatic tumours (T1-T3, N0M0) treated between 2018-2024. Patients underwent complete preoperative staging including contrast-enhanced CT and urethrocystoscopy. Surgical time averaged 72.5 minutes with minimal complications: one minor intraoperative complication and no major postoperative complications. Postoperative urinary continence improved significantly during follow-up, with 68.2% achieving full continence and 31.8% experiencing only mild persistent incontinence. No dogs developed severe permanent incontinence. Tumour progression occurred in 27.3% of cases at a median of 150 days post-surgery. Median follow-up and survival times were 570 and 900 days respectively. The study demonstrates that nerve-sparing total prostatectomy is a viable treatment option for carefully selected dogs with localized prostatic disease, offering excellent functional outcomes and encouraging survival rates with acceptable surgical morbidity.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.